Background of the invention
[0001] The present invention relates to assays and methods for identifying or for testing
agents which are modulators of a serine-threonine phosphatase PPM1E and can be used
for treating and preventing neurodegenerative disorders.
The present invention relates to methods of diagnosing, prognosticating and monitoring
the progression of neurodegenerative diseases.
The present invention relates to the treatment and prevention of neurodegenerative
disorders, more particularly to the treatment and prevention of Alzheimer's disease.
[0002] Neurodegenerative diseases, in particular Alzheimer's disease (AD), have a strongly
debilitating impact on a patient's life. Furthermore, these diseases constitute an
enormous health, social, and economic burden. AD is the most common neurodegenerative
disease, accounting for about 70 % of all dementia cases, and it is probably the most
devastating age-related neurodegenerative condition affecting about 10 % of the population
over 65 years of age and up to 45 % over age 85 (
Wimo et al., Alzheimer Dis. Assoc. Dis. 2003, 17:63-67;
Walsh and Selkoe, Neuron 2004, 44:181-193). Presently, this amounts to an estimated 12 million cases in the US, Europe, and
Japan. This situation will inevitably worsen with the demographic increase in the
number of old people in developed countries. The neuropathological hallmarks that
occur in the brains of individuals with AD are senile plaques, composed of amyloid-β
protein, and profound cytoskeletal changes coinciding with the appearance of abnormal
filamentous structures and the formation of neurofibrillary tangles (
Selkoe and Kopan, Annu Rev Neurosci 2003, 26:565-597;
Saido and lwata, Neurosci. Res. 2006, 54:235-253;
Braak and Braak, J Neural Transm 1998, 53: 127-140;
Schmitt et al., Neurology 2000, 55: 370-376).
[0003] Currently, there is no cure for AD, nor is there an effective treatment to halt the
progression of AD or even to diagnose AD ante-mortem with high probability.
[0004] Although there are rare examples of early-onset AD which have been attributed to
genetic defects in the genes for amyloid precursor protein (APP) on chromosome 21,
presenilin-1 on chromosome 14, and presenilin-2 on chromosome 1 , the prevalent form
of late-onset sporadic AD is of hitherto unknown etiologic origin. The late onset
and complex pathogenesis of neurodegenerative disorders pose a formidable challenge
to the development of therapeutic and diagnostic agents. It is crucial to expand the
pool of drug targets and diagnostic markers.
[0005] It is therefore an object of the present invention to provide insight into the pathogenesis
of neurodegenerative diseases and to provide methods, materials, agents and compositions
which are suited inter alia for the diagnosis and the prevention and treatment of
these diseases. This object has been solved by the features of the independent claims.
The subclaims define preferred embodiments of the present invention.
[0006] The present invention discloses the use of protein phosphatase 1 E (PPM1E) in methods
for identifying or for testing agents for the treatment or prevention of neurodegenerative
diseases and the use of PPM1E in diagnostic methods. A gene of the protein phosphatase
2C superfamily, coding for the protein phosphatase 1 E (PPM1E) and protein products
thereof is dysregulated, is differentially expressed in human Alzheimer's disease
brain samples. PPM1E has been formerly known as CaM kinase phophatase N (CaMKP-N)
or as Partner of PIX 1 (POPX1); such formerly used gene symbols CaMKP-N or POPX1 have
been exchanged to PPM1E in accordance with the HUGO (Human Genome Organisation) gene
nomenclature.
[0007] Protein phosphatases are the counterparts of kinases in a variety of complex regulatory
mechanisms of cellular functions like stress-activated signal transduction, mitogenic
signal transduction, and cell cycle control. PPM1E is a serine-threonine phosphatase
of 755 amino acids (84.0 kDa) that was identified as cDNA KIAA1072 in a project to
accumulating basic information of unidentified human genes (Genbank accession number
AB028995; REFSEQ accession number NM 014906;
Kikuno et al., DNA Res. 1999, 6:197-205). The PPM1E gene is located on chromosome 17q22. PPM1E is also known as partner of
PIX (POPX1) (Genbank accession number AF520614;
Koh et al., Current Biology 2002, 12:317-321), as PP2CH (Genbank accession number AF260269; unpublished), and in the rat as nuclear
calmodulin-dependent protein kinase phosphatase (CaMKP-N) (Genbank accession number
AB081729;
Takeuchi et al., J. Biochem. 2001, 130:833-840).
PPM1E was identified and characterized as substrate-specific phosphatase that dephosphorylates
and concomitantly deactivates Ca2+/calmodulin-dependent protein kinases (CaMKs) such
as CaMKI, CaMKII, and CaMKIV (
Takeuchi et al., J. Biochem. 2001, 130:833-840). Enzymatic activity of PPM1E requires Mn2+ ions and is activated by polycations
(
Takeuchi et al., J. Biochem. 2001, 130:833-840;
Ishida et al., Arch. Biochem. Biophys. 2002, 408:229-238). PPM1 E was shown to be specifically expressed in brain (
Takeuchi et al., J. Biochem. 2001, 130:833-840); in rat neurons PPM1E is present in the nucleus, in the cytoplasm and concentrated
at synaptic sites (
Kitani et al., J. Neurochem. 2006, 96:374-384). PPM1 E exists in two forms, as full length protein carrying different nuclear localization
signals at the C-terminus (
Takeuchi et al., J. Biochem. 2004, 136:183-188), as well as a posttranslationally C-terminal truncated form that lack a nuclear
localization signal (
Kitani et al., J. Neurochem. 2006, 96:374-384). In addition to the CaMK-specific phosphatase activity it is reported that PPM1E
forms a complex with Rho guanine nucleotide exchange factor 6 (ARHGEF6) and Serine/threonine-protein
kinase PAK 1 (PAK1) and thereby antagonizes cdc42-mediated activation of PAK1 (
Koh et al., Current Biology 2002, 12:317-321). A relation of PPM1E with neurodegenerative diseases, in particular with Alzheimer's
disease, has not been disclosed so far.
Brief description of the drawings
[0008]
Figure 1A lists the data for the identification of differences in the levels of PPM1E
gene derived mRNA in human brain tissue samples from individuals corresponding to
different Braak stages indicative for AD as measured by quantitative RT-PCR analysis.
Figure 1B demonstrates a substantial difference in gene expression level of PPM1 E
by comparison between samples representing different Braak stages.
Figure 2 shows the analysis of absolute levels of PPM1 E gene derived mRNA in human
brain tissue samples from individuals corresponding to different Braak stages indicative
for AD as measured by quantitative RT-PCR and using statistical method of the median
at 98 %-confidence level.
Figure 3A discloses SEQ ID NO: 1, the amino acid sequence of the human PPM1E full
length protein.
Figure 3B discloses SEQ ID NO: 2, the amino acid sequence of the human PPM1E posttranslationally
truncated protein.
Figure 4 shows SEQ ID NO: 3, the nucleotide sequence of the human PPM1E variant 1
cDNA.
Figure 5 shows SEQ ID NO: 4, the coding sequence (cds) of the human PPM1E.
Figure 6 depicts the sequence alignment of the primers used for PPM1E transcription
level profiling by quantitative RT-PCR with the corresponding clippings of PPM1 E
coding sequence.
Figure 7 shows the principle of a direct phosphatase assay.
Figure 8 shows the principle of an indirect phosphatase assay.
Summary of the invention
[0009] The present invention provides methods for diagnosing, prognosticating and monitoring
the progression of Alzheimer's disease, and for determining whether a subject is at
increased risk of developing Alzheimer's disease. More particularly, the present invention
provides assays and methods for the identification and for testing of agents binding,
modulating a serine-threonine phosphatase PPM1E. Said agents are useful in the treatment
and prevention of neurodegenerative disorders. The invention relates to the treatment
and prevention of neurodegenerative disorders, particularly to the treatment of Alzheimer's
disease using the PPM1E gene and/or its corresponding gene products and/or binding,
modulating agents of the PPM1E gene and/or PPM1E gene products.
[0010] The singular forms "a", "an", and "the" as used herein and in the claims include
plural reference unless the context dictates otherwise. For example, "a cell" means
as well a plurality of cells, and so forth.
The term "and/or" as used in the present specification and in the claims implies that
the phrases before and after this term are to be considered either as alternatives
or in combination. For instance, the wording "determination of a level and/or an activity"
means that either only a level, or only an activity, or both a level and an activity
are determined.
The term "level" as used herein is meant to comprise a gage of, or a measure of the
amount of, or a concentration of a substance such as a transcription product, for
instance an mRNA, or a translation product, for instance a protein or polypeptide.
The term "activity" as used herein shall be understood as a measure for the ability
of a substance, such as transcription product or a translation product to produce
a biological effect or a measure for a level of biologically active molecules. The
term "activity" also refers to biological activity and/or pharmacological activity
which refer to binding, antagonization, repression, blocking, neutralization or sequestration
of a transporter or transporter subunit and which refers to activation, agonization,
and up-regulation of a transporter or transporter subunit. "Enzymatic" activity shall
be the activity of an enzyme,as for example the activity of a phosphatase to dephosphorylate
a phosphorylated substrate.
The terms "level" and/or "activity" as used herein further refer to gene expression
levels or gene activity. Gene expression can be defined as the utilization of the
information contained in a gene by transcription and translation leading to the production
of a gene product. The measured "expression level" is an indicator for the amount
of transcription or translation product produced.
"Dysregulation" shall mean an up-regulation, an increase, an elevation or a down-regulation,
decrease, lowering of gene expression and/or an increase or decrease in the stability
of the gene products. A "gene product" comprises either RNA or protein and is the
result of expression of a gene. "Gene products" shall be any product, including full-length,
fragments, derivatives, variants, posttranslationally truncated products, derived
from the expression of a gene. The amount of a gene product can be used to measure
how active a gene is and how stable its gene products are.
The term "gene" as used in the present specification and in the claims comprises both
coding regions (exons) as well as non-coding regions (e.g. non-coding regulatory elements
such as promoters or enhancers, introns, leader and trailer sequences).
The term "ORF" is an acronym for "open reading frame" and refers to a nucleic acid
sequence that does not possess a stop codon in at least one reading frame and therefore
can potentially be translated into a sequence of amino acids.
"Regulatory elements" shall comprise inducible and non-inducible promoters, enhancers,
operators, and other elements that drive and regulate gene expression.
"Fragments" are understood to be any shorter or longer version of a gene, a gene product
of the PPM1E gene, protein. The term "fragment" as used herein is meant to comprise
e.g. an alternatively spliced, or truncated, or otherwise cleaved transcription product
or translation product. For example, the proteins having SEQ ID NO: 1 and SEQ ID NO:
2 are translation products of the gene coding for PPM1E proteins and posttranslationally
truncated products, fragments. The fragments on the nucleic acid level are coding
for proteins which have still a comparable and significant functionality of the PPM1E
proteins, the fragments on the protein level remain a comparable and significant functionality
of the PPM1E proteins.
The term "derivative" as used herein refers to a mutant, or an RNA-edited, or a chemically
modified, or otherwise altered transcription product, or to a mutant, or chemically
modified, or otherwise altered translation product. For the purpose of clarity, a
derivative transcript, for instance, refers to a transcript having alterations in
the nucleic acid sequence such as single or multiple nucleotide deletions, insertions,
or exchanges. A derivative translation product, for instance, may be generated by
processes such as altered phosphorylation, or glycosylation, or acetylation, or lipidation,
or by altered signal peptide cleavage or other types of maturation cleavage which
may occur post-translationally. A posttranslationally truncated translation product
is considered as a derivative of a translation product.
The term "modulator", "modulating agent", as used in the present invention and in
the claims refers to a molecule, an agent capable of modulating, of regulating, of
changing, altering the level and/or the activity of a gene, or a transcription product
of a gene, or a translation product of a gene or any substrate of said gene product.
A "modulator", "modulating agent" refers to a molecule which has the capacity to either
increase, enhance or decrease, inhibit, thus to "modulate" a functional property of
a protein, to "modulate" binding, antagonization, repression, blocking, neutralization
or sequestration, activation, agonization and regulation. "Modulation" will be also
used to refer to the capacity to affect the biological activity of a cell. Preferably,
a "modulator" is capable of changing or altering the biological activity of a transcription
product or a translation product of a gene. Said modulation, for instance, may be
an increase or a decrease in the biological activity and/or pharmacological activity,
a change in binding characteristics, or any other change or alteration in the biological,
functional, or immunological properties of said translation product of a gene.
The terms "agent", "reagent", or "compound" refer to any substance, chemical, composition,
or extract that have a positive or negative biological effect on a cell, tissue, body
fluid, a substrate, another molecule, or within the context of any biological system,
or any assay system examined. They can be agonists, antagonists, partial agonists
or inverse agonists of a target. Such agents, reagents, or compounds may be nucleic
acids, natural or synthetic peptides or protein complexes, or fusion proteins. They
may also be antibodies, organic or anorganic molecules or compositions, small molecules,
drugs and any combinations of any of said agents above. They may be used for testing,
for diagnostic or for therapeutic purposes and for screening methods.
The terms "oligonucleotide primer" or "primer" refer to short nucleic acid sequences
which can anneal to a given target polynucleotide by hybridization of the complementary
base pairs and can be extended by a polymerase. They may be chosen to be specific
to a particular sequence or they may be randomly selected, e.g. they will prime all
possible sequences in a mix. The length of primers used herein may vary from 10 nucleotides
to 80 nucleotides. "Probes" are short nucleic acid sequences of the nucleic acid sequences
described and disclosed herein or sequences complementary therewith. They may comprise
full length sequences, or fragments, derivatives, isoforms, or variants of a given
sequence. The identification of hybridization complexes between a "probe" and an assayed
sample allows the detection of the presence of other similar sequences within that
sample.
As used herein, "homolog or homology" is a term used in the art to describe the relatedness
of a nucleotide or peptide sequence to another nucleotide or peptide sequence, which
is determined by the degree of identity and/or similarity between said sequences compared.
In the art, the terms "identity" and "similarity" mean the degree of polypeptide or
polynucleotide sequence relatedness which are determined by matching a query sequence
and other sequences of preferably the same type (nucleic acid or protein sequence)
with each other. Preferred computer program methods to calculate and determine "identity"
and "similarity" include, but are not limited to GCG BLAST (Basic Local Alignment
Search Tool) (
Altschul et al., J. Mol. Biol. 1990, 215: 403-410;
Altschul et al., Nucleic Acids Res. 1997, 25: 3389-3402;
Devereux et al., Nucleic Acids Res. 1984, 12: 387), BLASTN 2.0 (Gish W., 1996-2002), FASTA (
Pearson and Lipman, Proc. Natl. Acad. Sci. USA 1988, 85: 2444-2448), and GCG GelMerge which determines and aligns a pair of contigs with the longest
overlap (
Wilbur and Lipman, SIAM J. Appl. Math. 1984, 44: 557-567;
Needleman and Wunsch, J. Mol. Biol. 1970, 48: 443-453).
The term "variant" as used herein refers to any polypeptide or protein, in reference
to polypeptides and proteins disclosed in the present invention, in which one or more
amino acids are added and/or substituted and/or deleted and/or inserted at the N-terminus,
and/or the C-terminus, and/or within the native amino acid sequences of the native
polypeptides or proteins of the present invention, but retains its essential properties.
Furthermore the term "variant" as used herein refers to any mRNA, in reference to
gene transcripts disclosed in the present invention, in which one or more nucleotides
are added and/or substituted and/or deleted.
Furthermore, the term "variant" shall include any shorter or longer version of a polypeptide
or protein. "Variants" shall also comprise a sequence that has at least about 80 %
sequence identity, more preferably at least about 85 % sequence identity, and most
preferably at least about 90 % sequence identity over a length of at least 200 amino
acids of PPM1 E proteins having SEQ ID NO: 1, or SEQ ID NO: 2: or of fragments of
said PPM1E proteins. "Variants" also include, for example, proteins with conservative
amino acid substitutions in highly conservative regions.
Furthermore, the term "variant" shall include any shorter or longer version of a gene
transcript, of a translation product. "Variants" shall also comprise a sequence that
has at least about 80 % sequence identity, more preferably at least about 85 % sequence
identity, and most preferably at least about 90 % sequence identity over a length
of at least 600 nucleotides of PPM1E gene transcripts having SEQ ID NO: 3, or SEQ
ID NO: 4 or of fragments of said PPM1E gene transcripts. Sequence variations shall
be included wherein a codon is replaced with another codon due to alternative base
sequences, but the amino acid sequence translated by the DNA sequence remains unchanged.
This known in the art phenomenon is called redundancy of the set of codons which translate
specific amino acids.
"Proteins and polypeptides" of the present invention include variants, fragments and
chemical derivatives of the proteins comprising the amino acid sequences of PPM1E
proteins having SEQ ID NO: 1, or SEQ ID NO: 2. Included shall be such exchange of
amino acids which would have no effect on functionality, such as arginine for lysine,
valine for leucine, asparagine for glutamine. Proteins and polypeptides can be included
which can be isolated from nature or be produced by recombinant and/or synthetic means.
Native proteins or polypeptides refer to naturally-occurring truncated or secreted
forms, naturally occurring variant forms (e.g. splice-variants) and naturally occurring
allelic variants.
The term "isolated" as used herein is considered to refer to molecules or substances
which have been changed and/or that are removed from their natural environment, i.e.
isolated from a cell or from a living organism in which they normally occur, and that
are separated or essentially purified from the coexisting components with which they
are found to be associated in nature. This notion further means that the sequences
encoding such molecules can be linked by the hand of man to polynucleotides, to which
they are not linked in their natural state and such molecules can be produced by recombinant
and/or synthetic means, it is also said that they are "non-native". Even if for said
purposes those sequences may be introduced into living or non-living organisms by
methods known to those skilled in the art, and even if those sequences are still present
in said organisms, they are still considered to be isolated. In the present invention,
the terms "risk", "susceptibility", and "predisposition" are tantamount and are used
with respect to the probability of developing a neurodegenerative disease, preferably
Alzheimer's disease.
"Neurodegenerative diseases or disorders" according to the present invention comprise
Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral
sclerosis, Pick's disease, fronto-temporal dementia, progressive nuclear palsy, corticobasal
degeneration, cerebro-vascular dementia, multiple system atrophy, argyrophilic grain
dementia and other tauopathies, and mild-cognitive impairment. Further conditions
involving neurodegenerative processes are, for instance, ischemic stroke, age-related
macular degeneration, narcolepsy, motor neuron diseases, prion diseases, traumatic
nerve injury and repair, and multiple sclerosis.
The term "AD" shall mean Alzheimer's disease. "AD-type neuropathology", "AD pathology"
as used herein refers to neuropathological, neurophysiological, histopathological
and clinical hallmarks, signs and symptoms as described in the instant invention and
as commonly known from state-of-the-art literature (see:
lqbal, Swaab, Winblad and Wisniewski, Alzheimer's Disease and Related Disorders (Etiology,
Pathogenesis and Therapeutics), Wiley & Sons, New York, Weinheim, Toronto, 1999;
Scinto and Daffner, Early Diagnosis of Alzheimer's Disease, Humana Press, Totowa,
New Jersey, 2000;
Mayeux and Christen, Epidemiology of Alzheimer's Disease: From Gene to Prevention,
Springer Press, Berlin, Heidelberg, New York, 1999;
Younkin, Tanzi and Christen, Presenilins and Alzheimer's Disease, Springer Press,
Berlin, Heidelberg, New York, 1998).
[0011] The term "Braak stage" or "Braak staging" refers to the classification of brains
according to the criteria proposed by Braak and Braak (
Braak and Braak, Acta Neuropathology 1991, 82: 239-259). Braak staging of AD rates the extent and distribution of neurofibrillary pathology
in determined regions of the forebrain and divides the neuropathologic progression
of AD into six stages (stage 0 to 6). It is a well established and universally accepted
procedure in post-mortem neuropathological staging of AD. It has convincingly been
shown that there is a significant correlation between an AD patient's clinical condition
with respect to mental status and cognitive function/impairment and the corresponding
Braak stage obtained after autopsy (
Bancher et al., Neuroscience Letters 1993, 162:179-182;
Gold et al., Acta Neuropathol. 2000, 99: 579-582). Likewise, a correlation between neurofibrillary changes and neuronal cellular pathology
has been found (
Rössler et al., Acta Neuropathol. 2002, 103:363-369), and both have been reported to predict cognitive function (
Giannakopoulos et al., Neurology 2003, 60:1495-1500;
Bennett et al., Arch. Neurol. 2004, 61 :378-384). Moreover, a pathogenic cascade has been proposed that involves the deposition of
beta-amyloid peptide and finally cumulates in the formation of neurofibrillary tangles,
the latter thus witnessing the precedence of earlier AD-specific events at the molecular/cellular
level (
Metsaars et al., Neurobiol. Aging 2003, 24:563-572).
[0012] In the instant invention, Braak stages are therefore used as a surrogate marker of
disease progression independent of the clinical presentation/condition of the individual
donor, i.e. independent of the presence or absence of reported mental illness, cognitive
deficits, decline in other neuropsychiatric parameters, or the overt clinical diagnosis
of AD. I.e. it is presumed that the neurofibrillary changes on which the Braak staging
reflect the underlying molecular and cellular pathomechanisms in general and hence
define a (pre-)morbid condition of the brain, meaning that e.g. a donor staged Braak
1 represents by definition an earlier stage of molecular/cellular pathogenesis than
a donor staged 2 (or higher), and that therefore a donor of Braak stage 1 can e.g.
be regarded as a control individual when compared to donors of any higher Braak stage.
In this regard, the differentiation between control individual and affected individual
may not necessarily be the same as the clinical diagnosis based differentiation between
healthy control donor and AD patient, but it rather refers to a presumed difference
in the (pre-) morbid status as deduced from and mirrored by a surrogate marker, the
Braak stage.
[0013] In the instant invention Braak stage 0 may represent persons which are not considered
to suffer from Alzheimer's disease signs and symptoms, and Braak stages 1 to 4 may
represent either healthy control individuals or AD patients depending on whether said
individuals were suffering already from clinical signs and symptoms of AD. The higher
the Braak stage the more likely is the possibility to display signs and symptoms of
AD or the risk to develop signs and symptoms of AD. For a neuropathological assessment,
i.e. an estimation of the probability that pathological changes of AD are the underlying
cause of dementia, a recommendation is given by Braak H (
Braak and Braak, Acta Neuropathology 1991, 82: 239-259).
[0014] The values obtained from controls are the reference values representing a known health
status and the values obtained from patients are the reference values representing
a known disease status.
Detailed description of the invention
[0015] The gene of the protein phosphatase 1 E, also named PPM1E, and the gene productsof
said gene PPM1E, are differentially expressed, differentially regulated, dysregulated
in specific samples, in specific brain regions of AD patients, in specific brain regions
of individuals grouped into different Braak stages, in comparison with each other
and/or in comparison to age-matched control individuals. The gene expression for PPM1E
is varied, is dysregulated in brains of AD patients as compared to the respective
brain regions of control individuals, in that PPM1E mRNA levels are increased, are
up-regulated in the inferior temporal cortex and in the frontal cortex of AD patients
compared to controls. Further, PPM1E expression differs in specific brain regions
of individuals grouped into different Braak stages with an increase in expression
level starting already at early Braak stages and with a progressive increase with
the course of Braak stages (Braak 1-3).
Linking the PPM1 E gene to diseases as for example Alzheimer's disease offers new
ways, inter alia, for the diagnosis and prevention and treatment of said diseases.
Linking PPM1E to pathological events occurring already early in the course of AD provides
the possibility of a treatment which will prevent the initiation of AD pathology,
a treatment which will be applied before non-repairable damages of the brain occur.
Consequently, the present invention has utility for diagnostic evaluation, for diagnostic
monitoring of persons undergoing a treatment, for prognosis as well as for the identification
of a predisposition to a neurodegenerative disease, in particular AD. Furthermore,
the present invention has utility for using PPM1E in assays and in methods for identifying
and for testing agents, modulators, which are useful in the treatment and prevention
of neurodegenerative disorders.
Neurons within the inferior temporal lobe, the entorhinal cortex, the hippocampus,
and the amygdala, thus, neurons within specific brain regions are subject to degenerative
processes in AD (
Terry et al., Annals of Neurology 1981, 10:184-192). These brain regions are mostly involved in the processing of learning and memory
functions and display a selective vulnerability to neuronal loss and degeneration
in AD. Brain tissues from the frontal cortex (F) and the inferior temporal cortex
(T) of AD patients and of age-matched controls were used for herein described examples.
Consequently, the PPM1E gene and its corresponding transcription and/or translation
products play a causative role, and/or have an influence on the selective neuronal
degeneration.
[0016] In one aspect, the invention features a method of diagnosing or prognosticating a
neurodegenerative disease in a subject, or of determining whether a subject has a
predisposition of developing said disease, is at increased risk of developing said
disease, or of monitoring the effect of a treatment administered to a subject having
a neurodegenerative disease. The method comprises: determining a level, an expression
or an activity, or both said level, expression and said activity of (i) a transcription
product of a gene coding for PPM1E proteins, and/or of (ii) a translation product
of a gene coding for PPM1E proteins, and/or of (iii) a fragment, or derivative, or
variant of said transcription or translation product in a sample obtained from said
subject and comparing said level, expression and/or said activity of said transcription
product and/or said translation product and/or said fragment, derivative or variant
thereof to a reference value representing a known disease status (patient) and/or
to a reference value representing a known health status (control), and/or to a reference
value representing a known Braak stage and analysing whether said level and/or said
activity is varied, is altered compared to a reference value representing a known
health status, and/or is similar or equal to a reference value representing a known
disease status and/or is similar compared to a reference value representing a known
Braak stage which is an indication that said subject has a neurodegenerative disease,
or that said subject is at increased risk of developing signs and symptoms of said
disease, thereby diagnosing or prognosticating said neurodegenerative disease in said
subject, or determining whether said subject is at increased risk of developing said
neurodegenerative disease.
The wording "in a subject" refers to results of the methods disclosed as far as they
relate to a disease afflicting a subject, that is to say, said disease being "in"
a subject.
[0017] In a further aspect, the invention features a method of monitoring the progression
of a neurodegenerative disease in a subject. A level, expression or an activity, or
both said level, expression and said activity, of (i) a transcription product of a
gene coding for PPM1 E proteins, and/or of (ii) a translation product of a gene coding
for PPM1 E proteins, and/or of (iii) a fragment, or derivative, or variant of said
transcription or translation product in a sample obtained from said subject is determined.
Said level, expression and/or said activity are compared to a reference value representing
a known disease or health status or a known Braak stage. Thereby, the progression
of said neurodegenerative disease over a period of time in said subject is monitored.
[0018] In still a further aspect, the invention features a method of evaluating a treatment
or monitoring the effect of a treatment for a neurodegenerative disease, comprising
determining a level, expression or an activity, or both said level, expression and
said activity of (i) a transcription product of a gene coding for PPM1E proteins,
and/or of (ii) a translation product of a gene coding for PPM1E proteins, and/or of
(iii) a fragment, or derivative, or variant of said transcription or translation product
in a sample obtained from a subject being treated for said disease. Said level, expression
or said activity, or both said level, expression and said activity are compared to
a reference value representing a known disease or health status or a known Braak stage
which was not subject of a treatment, thereby evaluating the treatment for said neurodegenerative
disease.
[0019] In a preferred embodiment of said method of monitoring, method of evaluating, of
monitoring the effect of a treatment, the level, expression or the activity, or both
said level and said activity of (i) a transcription product of a gene coding for PPM1E
proteins, and/or of (ii) a translation product of a gene coding for PPM1E proteins,
and/or of (iii) a fragment, or derivative, or variant of said transcription or translation
product in a series of samples taken from said subject over a period of time is compared,
in order to monitor the progression of said disease. In further preferred embodiments,
said subject receives a treatment prior to one or more of said sample gatherings.
In yet another preferred embodiment, said level and/or activity is determined before
and after said treatment of said subject.
[0020] It is preferred that said level, the expression and/or said activity of said transcription
product and/or said translation product of PPM1E and of its fragments, derivatives,
or variants, is increased, is up-regulated in samples obtained from AD patients as
compared to samples obtained from persons not suffering from AD, control persons.
For example, the expression and/or activity of the transcription product and/or the
translation product of PPM1E and of its fragments, derivatives, or variants is measured
from samples of patients and compared with the expression and/or activity of the transcription
product and/or the translation product of PPM1 E and of its fragments, derivatives,
or variants in a sample of a healthy control subject (reference sample).
[0021] In a preferred embodiment of the herein claimed uses, assays, methods, methods of
diagnosing, methods of identifying, methods of testing, methods of screening, herein
claimed kits, agents and materials of the instant invention, said PPM1E gene codes
for proteins having SEQ ID NO: 1, variant or derivative or fragment no.1 (full length
protein of PPM1E, UniProt primary accession number Q8WY54), or SEQ ID NO: 2, variant
or derivative or fragment no. 2 (posttranslationally truncated protein of PPM1E Q8WY54).
The amino acid sequences of said variants are deduced from the mRNA sequences of SEQ
ID NO: 3 which correspond to the cDNA sequence of Ensembl transcript ID number ENST00000308249.
In the instant invention PPM1E also refers to the nucleic acid sequences SEQ ID NO:
4 representing the coding sequences (cds) of human PPM1E. In the instant invention
said sequences are "isolated" as the term is employed herein. Further, in the instant
invention, the gene coding for said PPM1E proteins (full length form and posttranslationally
truncated form) is also generally referred to as the PPM1E gene or simply PPM1E. The
proteins (full length form and posttranslationally truncated form) of PPM1E are also
generally referred to as the PPM1E proteins, PPM1E variants, derivatives, fragments
or simply PPM1 E.
[0022] In a further preferred embodiment of the herein claimed methods, assays, kits, agents,
materials and uses of the instant invention, said neurodegenerative disease or disorder
is Alzheimer's disease, and said subjects may suffer from signs and symptoms of Alzheimer's
disease.
[0023] It is preferred that the sample to be analyzed and determined is selected from the
group comprising brain tissue or other tissues, or body cells. The sample can also
comprise cerebrospinal fluid or other body fluids including saliva, urine, stool,
blood, serum plasma, or mucus. Preferably, the methods of diagnosis, prognosis, monitoring
the progression or evaluating a treatment for a neurodegenerative disease, according
to the instant invention, can be practiced ex
corpore, and such methods preferably relate to samples, for instance, body fluids or cells,
removed, collected, or isolated from a subject or patient or a control person.
[0024] In further preferred embodiments, said reference value is that of a level, of expression,
or of an activity, or both of said level and said activity of (i) a transcription
product of the gene coding for PPM1E proteins, and/or of (ii) a translation product
of the gene coding for PPM1E proteins, and/or of (iii) a fragment, or derivative,
or variant of said transcription or translation product in a sample obtained from
a subject not suffering from said neurodegenerative disease (control sample, control,
healthy control person) or in a sample obtained from a subject suffering from a neurodegenerative
disease, in particular Alzheimer's disease (patient sample, patient, AD sample) or
from a person with a defined Braak stage which may suffer or may not suffer from signs
and symptoms of AD.
[0025] In preferred embodiments, an alteration in the level and/or activity and/or expression
of a transcription product of the gene coding for PPM1E proteins and/or of a translation
product of the gene coding for PPM1 E proteins and/or of a fragment, or derivative,
or variant thereof in a sample cell, or tissue, or body fluid taken from said subject
relative to a reference value representing a known health status (control sample)
indicates a diagnosis, or prognosis, or increased risk of becoming diseased with a
neurodegenerative disease, particularly AD.
[0026] In a further preferred embodiment, an equal or similar level and/or activity and/or
expression of a transcription product of the gene coding for PPM1E proteins and/or
of a translation product of the gene coding for PPM1 E proteins and/or of a fragment,
or derivative, or variant thereof in a sample cell, or tissue, or body fluid obtained
from a subject relative to a reference value representing a known disease status of
a neurodegenerative disease, in particular Alzheimer's disease (AD patient sample),
indicates a diagnosis, or prognosis, or increased risk of becoming diseased with said
neurodegenerative disease.
In another further preferred embodiment, an equal or similar level, expression and/or
activity of a transcription product of the gene coding for PPM1 E proteins and/or
of a translation product of the gene coding for PPM1 E proteins and/or of a fragment,
or derivative, or variant thereof in a sample cell, or tissue, or body fluid obtained
from a subject relative to a reference value representing a known Braak stage which
Braak stage reflects a high risk of developing signs and symptoms of AD, indicates
a diagnosis, or prognosis, or an increased risk of becoming diseased with AD.
[0027] It is preferred however that said varied, altered level, altered expression and/or
said altered activity of said transcription product and/or said translation product
of PPM1 E and of its fragments, derivatives, or variants, is an increase, an up-regulation.
[0028] In preferred embodiments, measurement of the level of transcription products and/or
of expression of the gene coding for PPM1E proteins is performed in a sample obtained
from a subject using a quantitative PCR-analysis with primer combinations to amplify
said gene specific sequences from cDNA obtained by reverse transcription of RNA extracted
from a sample of a subject. Primer combinations (SEQ ID NO: 5, SEQ ID NO: 6) are given
in Example 1 (iii) of the instant invention, but also other primers generated from
the sequences as disclosed in the instant invention can be used. A Northern blot or
a ribonuclease protection assay (RPA) with probes specific for said gene can also
be applied. These techniques are known to those of ordinary skill in the art (see
Sambrook and Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, New York, 2001). An example of an immunoassay is the detection and measurement of enzyme activity
as disclosed and described in the patent application
WO02/14543.
[0029] The invention also relates to the construction and the use of primers and probes
which are unique to the nucleic acid sequences, or fragments, or variants thereof,
as disclosed in the present invention. The oligonucleotide primers and/or probes can
be labeled specifically with fluorescent, bioluminescent, magnetic, or radioactive
substances. The invention further relates to the detection and the production of said
nucleic acid sequences, or fragments and variants thereof, using said specific oligonucleotide
primers in appropriate combinations. PCR-analysis, a method well known to those skilled
in the art, can be performed with said primer combinations to amplify said gene specific
nucleic acid sequences from a sample containing nucleic acids. Such sample may be
derived either from healthy or diseased subjects or subjects with defined Braak stages.
Whether an amplification results in a specific nucleic acid product or not, and whether
a fragment of different length can be obtained or not, may be indicative for a neurodegenerative
disease, in particular Alzheimer's disease. Thus, the invention provides nucleic acid
sequences, oligonucleotide primers, and probes of at least 10 bases in length up to
the entire coding and gene sequences, useful for the detection of gene mutations and
single nucleotide polymorphisms in a given sample comprising nucleic acid sequences
to be examined, which may be associated with neurodegenerative diseases, in particular
Alzheimer's disease. This feature has utility for developing rapid DNA-based diagnostic
tests, preferably also in the format of a kit. Primers for PPM1E are exemplarily described
in Example 1 (iii).
[0030] In another aspect, the invention features a kit for the methods of diagnosing, of
prognosticating neurodegenerative diseases in a subject, or determining the propensity
or predisposition of a subject to develop a neurodegenerative disease, or of monitoring
the effect of a treatment administered to a subject having a neurodegenerative disease,
said kit comprising:
- (a) at least one reagent which is selected from the group consisting of (i) reagents
that selectively detect a transcription product of the gene coding for PPM1E proteins
(ii) reagents that selectively detect a translation product of the gene coding for
PPM1E proteins; and/or (iii) reagents that detect a fragment or derivative or variant
of said transcription or translation product;
- (b) an instruction describing a method for diagnosing, or prognosticating a neurodegenerative
disease, or determining the propensity or predisposition of a subject to develop such
a disease or of monitoring the effect of a treatment as disclosed in the instant invention.
The kit, according to the present invention, may be particularly useful for the identification
of individuals that are at risk of developing a neurodegenerative disease, which neurodegenerative
disease is in particular AD.
Reagents that selectively detect a transcription product and/or a translation product
of the gene coding for PPM1E proteins, preferably coding for the variants having SEQ
ID NO: 1, or having SEQ ID NO: 2, can be sequences of various length, fragments of
sequences, antibodies, aptamers, siRNA, microRNA, and ribozymes. Such reagents may
be used also to detect fragments, derivatives or variants thereof.
In a further aspect the invention features the use of a kit in a method of diagnosing
or prognosticating a neurodegenerative disease, in particular Alzheimer's disease,
in a subject, and in a method of determining the propensity or predisposition of a
subject to develop such a disease, and in a method of monitoring the effect of a treatment
administered to a subject having a neurodegenerative disease, particularly AD.
Consequently, the kit, according to the present invention, may serve as a means for
targeting identified individuals for early preventive measures or therapeutic intervention
prior to disease onset, before irreversible damage in the course of the disease has
been inflicted. Furthermore, in preferred embodiments, the kit featured in the invention
is useful for monitoring a progression of a neurodegenerative disease, in particular
AD in a subject, as well as monitoring success or failure of therapeutic treatment
for such a disease of said subject.
[0031] Furthermore, a level and/or an activity and/or expression of a translation product
of the gene coding for PPM1E proteins and/or of a fragment, or derivative, or variant
of said translation product, and/or the level or activity of said translation product,
and/or of a fragment, or derivative, or variant thereof, can be detected using a binding
assay, an immunoassay, an activity assay. Activity assays can measure the enzymatic
activity of a protein, for example the phosphatase activity in an appropriate phosphatase
assay measuring the dephosphorylation of a phosphorylated substrate. Examples of such
activity assays are given in the instant invention (example 2). Binding assays can
measure the amount of binding between said protein molecule and an anti-protein antibody
by the use of enzymatic, chromodynamic, radioactive, magnetic, or luminescent labels
which are attached to either the anti-protein antibody or a secondary antibody which
binds the anti-protein antibody. In addition, other high affinity ligands may be used.
Immunoassays which can be used include e.g. ELISAs, Western blots and other techniques
known to those of ordinary skill in the art (see
Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, New York, 1999 and
Edwards R, Immunodiagnostics: A Practical Approach, Oxford University Press, Oxford;
England, 1999). All these detection techniques may also be employed in the format of microarrays,
protein-arrays, antibody microarrays, tissue microarrays, electronic biochip or protein-chip
based technologies (see
Schena M., Microarray Biochip Technology, Eaton Publishing, Natick, MA, 2000).
[0032] In one aspect, the invention features the use of (i) a gene coding for a protein
phosphatase 1 E, and/or of (ii) a transcription product of the gene coding for protein
phosphatase 1 E, and/or of (iii) a translation product of the gene coding for protein
phosphatase 1 E, and/or of (iv) a fragment, or derivative, or variant of (i) to (iii)
in a method for identifying agents or for testing agents for the treatment or prevention
of neurodegenerative diseases. Said agents identified and/or tested are modulators
of (i) to (iv). It is preferred that said gene coding for protein phosphatase 1 E
is the gene coding for a protein phosphatase 1 E protein having SEQ ID NO:1 or SEQ
ID NO: 2 and/or wherein said translation product of the gene coding for protein phosphatase
1 E proteins is the protein phosphatase 1 E protein having SEQ ID NO: 1 or SEQ ID
NO: 2. It is further preferred that said neurodegenerative disease is Alzheimer's
disease.
[0033] In another aspect, the invention features a method for identifying agents for the
treatment and/or prevention of neurodegenerative diseases, in particular AD, or related
diseases and disorders. Said method comprises (a) contacting an agent with a phosphorylated
substrate and with a translation product of the gene coding for protein phosphatase
1 E and/or a fragment, or derivative, or variant thereof, (b) measuring the enzymatic
activity of a translation product of the gene coding for protein phosphatase 1 E,
and/or a fragment, or derivative, or variant thereof, (c) comparing the enzymatic
activity measured in step (b) with the enzymatic activity of a translation product
of the gene coding for protein phosphatase 1 E, and/or a fragment, or derivative,
or variant thereof measured not contacted with said agent, (d) identifying agents
modulating the enzymatic activity of a translation product of the gene coding for
protein phosphatase 1 E and/or a fragment, or derivative, or variant thereof as agents
for the treatment and prevention of neurodegenerative disorders.
[0034] In a further aspect of the method for identifying agents for the treatment and/or
prevention of neurodegenerative diseases said (a) contacting of an agent with a phosphorylated
substrate and with a translation product of the gene coding for protein phosphatase
1 E and/or a fragment, or derivative, or variant thereof is in a sample wherein the
sample is an in vitro sample comprising an expression system for expression of PPM1E
or is a cell, a tissue, or a non-human animal comprising an expression system for
expression of PPM1 E.
[0035] In a further aspect, said method of identifying agents for the treatment and/or prevention
of neurodegenerative diseases by measuring the enzymatic activity of a translation
product of the gene coding for protein phosphatase 1 E is as well suitable for testing
agents, said testing may be a conformation testing of agents unknown or of agents
already known in the context of neurodegenerative disorders.
[0036] In a preferred embodiment said agents identified are modulators having the ability
to modulate, to alter the enzymatic activity of a translation product of the gene
coding for PPM1 E protein (preferably having SEQ ID NO: 1 or SEQ ID NO: 2), and/or
a fragment, or derivative, or variant thereof.
In a further preferred embodiment said enzymatic activity measured is a phosphatase
activity. Said phosphatase activity is measured by determination of the dephosphorylation
of a phosphorylated substrate.
[0037] In a preferred embodiment of said methods of identifying or of testing agents for
the treatment and/or prevention of neurodegenerative diseases said agents are identified
or tested which decrease the enzymatic activity of protein phosphatase 1 E.
In a further preferred embodiment of said methods of identifying or of testing agents
for the treatment and/or prevention of neurodegenerative diseases said agents are
identified or tested which inhibit the enzymatic activity of protein phosphatase 1
E.
[0038] In another aspect, the invention features a method for identifying agents for the
treatment and/or prevention of neurodegenerative diseases, in particular AD, or related
diseases and disorders. Said method comprises (a) contacting a sample comprising an
expression system for expression of protein phosphatase 1 E with an agent, (b) measuring
an expression level of gene coding for PPM1 E protein, and/or a transcription product
of the gene coding for PPM1 E protein and/or a translation product of the gene coding
for PPM1E protein and/or a fragment, or derivative, or variant thereof, in said sample,
(c) comparing the expression level measured in step (b) with an expression level of
gene coding for PPM1 E protein, and/or a transcription product of the gene coding
for PPM1 E protein and/or a translation product of the gene coding for PPM1E protein
and/or a fragment, or derivative, or variant thereof measured in a sample comprising
an expression system for expression of protein phosphatase 1 E not contacted with
said agent, (d) identifying agents modulating the expression level of a gene coding
for PPM1E protein, and/or a transcription product of the gene coding for PPM1E protein
and/or a translation product of the gene coding for PPM1E protein and/or a fragment,
or derivative, or variant thereof as agents for the treatment and prevention of neurodegenerative
disorders.
[0039] In a further aspect of the method for identifying agents for the treatment and/or
prevention of neurodegenerative diseases said sample comprising an expression system
for expression of protein phosphatase 1E is an in vitro sample or is a cell, a tissue,
or a non-human animal comprising an expression system for expression of PPM1 E.
[0040] In a further aspect, said method of identifying agents for the treatment and/or prevention
of neurodegenerative diseases by measuring an expression level of gene coding for
PPM1E protein, and/or a transcription product of the gene coding for PPM1E protein
and/or a translation product of the gene coding for PPM1E protein and/or a fragment,
or derivative, or variant thereof is as well suitable for testing agents, said testing
may be a conformation testing of agents unknown or of agents already known in the
context of neurodegenerative disorders.
[0041] In a preferred embodiment of said method of identifying or of testing agents for
the treatment and/or prevention of neurodegenerative diseases said agents are identified
or tested which decrease an expression level of the gene coding for PPM1E protein,
and/or a transcription product of the gene coding for PPM1E protein and/or a translation
product of the gene coding for PPM1E protein and/or a fragment, or derivative, or
variant thereof.
[0042] It is preferred that in said methods of identifying or of testing agents for the
treatment and/or prevention of neurodegenerative diseases the gene coding for protein
phosphatase 1 E is the gene coding for a protein phosphatase 1 E protein having SEQ
ID NO:1 or SEQ ID NO: 2 and/or wherein a transcription product of the gene coding
for PPM1 E protein is the gene coding for a PPM1 E protein having SEQ ID NO: 1 or
SEQ ID NO: 2, and/or wherein said translation product of the gene coding for protein
phosphatase 1 E proteins is the protein phosphatase 1 E protein having SEQ ID NO:
1 or SEQ ID NO: 2 and/or a fragment, or derivative, or variant thereof. It is further
preferred that said neurodegenerative disease is Alzheimer's disease.
[0043] In a further aspect the invention makes use of a cell, which cell comprises a nucleic
acid comprising a PPM1E sequence coding for a PPM1E protein (preferably having SEQ
ID NO: 1 or SEQ ID NO: 2), or a fragment, or derivative, or variant thereof. Said
cell may comprise an expression system for expression of PPM1E. Said cell may mis-express,
under-express, non-express or over-express, or express a disrupted or in another way
alterated PPM1E protein for identifying, testing, screening and validating agents,
compounds, modulators in the development of diagnostics and therapeutics to treat
and prevent neurodegenerative diseases, in particular Alzheimer's disease. In a preferred
embodiment said cell is used in a method of identifying or testing agents according
to the instant invention.
[0044] In one further aspect, the invention features methods of identifying, of testing
and of screening agents and uses according to the instant invention, wherein said
agents, test compounds are administered to a tissue or to a non-human animal which
non-human animal is predisposed to developing or has already developed signs and symptoms
of a neurodegenerative disease or related diseases or disorders, preferably symptoms
related to symptoms of Alzheimer's disease.
[0045] In a further aspect, the present invention provides a method for identifying agents
or for testing agents for the treatment or prevention of neurodegenerative diseases,
which agents are binding to a gene coding for protein phosphatase 1 E, and/or a transcription
product of the gene coding for protein phosphatase 1 E, and/or a translation product
of the gene coding for protein phosphatase 1 E, and/or a fragment, or derivative,
or variant thereof, or which agents modulating the binding between a substance and
a gene coding for protein phosphatase 1 E, and/or a transcription product of the gene
coding for protein phosphatase 1 E, and/or a translation product of the gene coding
for protein phosphatase 1 E, and/or a fragment, or derivative, or variant thereof.
In a preferred embodiment of the method for identifying agents or for testing agents
said agents modulating the binding between a substance and and a gene coding for protein
phosphatase 1 E, and/or a transcription product of the gene coding for protein phosphatase
1 E, and/or a translation product of the gene coding for protein phosphatase 1 E,
and/or a fragment, or derivative, or variant thereof, are modulating the binding by
inhibiting the binding or by enhancing the binding or by altering the degree of binding.
It is further preferred that said gene coding for protein phosphatase 1 E is the gene
coding for a protein phosphatase 1 E protein having SEQ ID NO:1 or SEQ ID NO: 2, and
wherein said translation product of the gene coding for protein phosphatase 1 E proteins
is the protein phosphatase 1 E protein having SEQ ID NO: 1 or SEQ ID NO: 2. It is
further preferred that said neurodegenerative disease is Alzheimer's disease.
[0046] In another aspect, the present invention provides for a method of screening, for
a method of identifying or testing agents, a compound or compounds, preferably for
screening, identifying, testing a plurality of agents, compounds in high-throughput
format, to determine the degree of inhibition of binding or the enhancement of binding
between a substance, ligand and PPM1E protein (preferably having SEQ ID NO: 1 or SEQ
ID NO: 2), or a fragment, or derivative, or variant thereof by an agent, a compound
and/or to determine the degree of binding of said agents, compounds to PPM1 E protein
(preferably having SEQ ID NO: 1 or SEQ ID NO: 2), or a fragment, or derivative, or
variant thereof. For determination of inhibition of binding between a substance, ligand
and PPM1E protein, or a fragment, or derivative, or variant thereof, said method of
screening, identifying, testing comprise the steps of (i) adding a liquid suspension
of said PPM1E protein, or a fragment, or derivative, or variant thereof, to a plurality
of containers, and (ii) adding an agent, compound or a plurality of agents, compounds
to be screened, tested for said inhibition to said plurality of containers, and (iii)
adding a detectable, preferably a fluorescently labelled substance, ligand to said
containers, and (iv) incubating said PPM1E protein, or said fragment, or derivative
or variant thereof, and said agent, compound or plurality of agents, compounds, and
said detectable, preferably fluorescently labelled substance, ligand, and (v) measuring
the amounts of substance, ligand, preferably its fluorescence, associated with said
PPM1E protein, or with said fragment, or derivative, or variant thereof, and (vi)
determining the degree of inhibition by one or more of said agents, compounds of binding
of said substance, ligand to said PPM1 E protein, or said fragment, or derivative,
or variant thereof. It might be preferred to reconstitute said PPM1E translation product,
or fragment, or derivative, or variant thereof into artificial liposomes to generate
the corresponding proteoliposomes to determine the inhibition of binding between a
substance, ligand and said PPM1E translation product. Methods of reconstitution of
PPM1 E translation products from detergent into liposomes have been detailed (
Schwarz et al., Biochemistry 1999, 38: 9456-9464;
Krivosheev and Usanov, Biochemistry-Moscow 1997, 62: 1064-1073). Instead of utilizing a fluorescently labelled substance, ligand, it might in some
aspects be preferred to use any other detectable label known to the person skilled
in the art, e.g. radioactive labels, and detect it accordingly. Said method may be
useful for the identification of novel agents, compounds as well as for evaluating
agents, compounds which have been improved or otherwise optimized in their ability
to inhibit the binding of a substance, ligand to a gene product of the gene coding
for PPM1E protein, or a fragment, or derivative, or variant thereof. One example of
a fluorescent binding assay, in this case based on the use of carrier particles, is
disclosed and described in patent application
WO00/52451. A further example is the competitive assay method as described in patent
WO02/01226. Preferred signal detection methods for screening assays of the instant invention
are described in the following patent applications:
WO96/13744,
WO98/16814,
WO99/34195,
WO00/66985, and
WO01/59416.
[0047] Furthermore, the present invention provides for a method of screening, for a method
of identifying or testing agents, a compound or compounds, preferably for screening,
identifying, testing a plurality of agents, compounds in high-throughput format, to
determine the degree of binding of said agents, compounds to PPM1E protein (preferably
having SEQ ID NO: 1 or SEQ ID NO: 2), or to a fragment, or derivative, or variant
thereof, said method of screening, identifying or testing comprises (i) adding a liquid
suspension of said PPM1E protein, or a fragment, or derivative, or variant thereof,
to a plurality of containers, and (ii) adding a detectable, preferably a fluorescently
labelled agent, compound or a plurality of detectable, preferably fluorescently labelled
agents, compounds to be screened for said binding to said plurality of containers,
and (iii) incubating said PPM1E protein, or said fragment, or derivative, or variant
thereof, and said detectable, preferably fluorescently labelled agent, compound or
detectable, preferably fluorescently labelled agents, compounds, and (iv) measuring
the amounts of agent, compound, preferably its fluorescence, associated with said
PPM1E protein, or with said fragment, or derivative, or variant thereof, and (v) determining
the degree of binding by one or more of said agents, compounds to said PPM1E protein,
or said fragment, or derivative, or variant thereof. In this type of screening method,
assay it might be preferred to use a fluorescent label. However, any other type of
detectable label might also be employed. Also in this type of assay it might be preferred
to reconstitute a PPM1E translation product or a fragment, or derivative, or variant
thereof into artificial liposomes as described in the present invention. Said assay
methods may be useful for the identification of novel agents, compounds as well as
for testing, evaluating agents, compounds which have been improved or otherwise optimized
in their ability to bind to PPM1E protein, or a fragment, or derivative, or variant
thereof.
[0048] In another aspect, the invention features a method of treating or preventing a neurodegenerative
disease, in particular AD, in a subject comprising the administration to said subject
in need of such a treatment in a therapeutically or prophylactically effective amount
and formulation an agent, modulating agents, modulators, compounds, antagonist, agonists
or antibodies which directly or indirectly affect a level and/or an activity, an expression
level and/or enzymatic activity, of (i) the gene coding for PPM1E proteins, and/or
(ii) a transcription product of the gene coding for PPM1 E proteins, and/or (iii)
a translation product of the gene coding for PPM1 E proteins, and/or (iv) a fragment,
or derivative, or variant of (i) to (iii). Said agent, compound may comprise a small
molecule, or it may also comprise a peptide, an oligopeptide, or a polypeptide. Said
peptide, oligopeptide, or polypeptide may comprise an amino acid sequence of a translation
product of the gene coding for PPM1 E proteins, or a fragment, or derivative, or a
variant thereof. An agent for treating or preventing a neurodegenerative disease,
in particular AD, according to the instant invention, may also consist of a nucleotide,
an oligonucleotide, or a polynucleotide. Said oligonucleotide or polynucleotide may
comprise a nucleotide sequence of the gene coding for PPM1E proteins, either in sense
orientation or in antisense orientation.
[0049] In another aspect, the invention provides for the use of an agent, an antibody, an
antagonist or agonist, or a modulator of an activity and/or a level, an enzymatic
activity and/or expression level of (i) the gene coding for PPM1E proteins, and/or
(ii) a transcription product of the gene coding for PPM1E proteins, and/or (iii) a
translation product of the gene coding for PPM1E proteins, and/or (iv) a fragment,
or derivative, or variant of (i) to (iii) in the manufacture of a medicament for treating
or preventing a neurodegenerative disease, in particular AD. Said antibody may be
specifically immunoreactive with an immunogen which is a translation product of a
gene coding for PPM1E (preferably having SEQ ID NO: 1 or SEQ ID NO: 2) or a fragment,
derivative or variant of such translation product.
In general, the aforementioned screening methods, methods of identifying, testing,
assays as well as potential drug molecules (e.g. agents, compounds, modulators, antagonists,
agonists) identified thereof have applicability in relation to the treatment or prevention
of neurodegenerative diseases, in particular Alzheimer's disease.
[0050] Another aspect of the present invention features protein molecules being translation
products of the gene coding for PPM1E and the use of said protein molecules (preferably
having SEQ ID NO: 1 or SEQ ID NO: 2), or fragments, or derivatives, or variants thereof,
as diagnostic targets for detecting a neurodegenerative disease, in particular Alzheimer's
disease.
[0051] The present invention further features protein molecules being translation products
of the gene coding for PPM1E and the use of said protein molecules (preferably having
SEQ ID NO: 1 or SEQ ID NO: 2), or fragments, or derivatives, or variants thereof,
as screening targets for agents, modulators, antagonists, agonists, reagents or compounds
preventing, or treating, or ameliorating a neurodegenerative disease, in particular
Alzheimer's disease.
[0052] The present invention features antibodies which are specifically immunoreactive with
an immunogen, wherein said immunogen is a translation product of the PPM1E gene coding
for PPM1E proteins (preferably having SEQ ID NO: 1 or SEQ ID NO: 2), or fragments,
or derivatives, or variants thereof. The immunogen may comprise immunogenic or antigenic
epitopes or portions of a translation product of said gene, wherein said immunogenic
or antigenic portion of a translation product is a polypeptide, and wherein said polypeptide
elicits an antibody response in an animal, and wherein said polypeptide is immunospecifically
bound by said antibody. Methods for generating antibodies are well known in the art
(see
Harlow et al., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, New York, 1988). The term "antibody", as employed in the present invention, encompasses all forms
of antibodies known in the art, such as polyclonal, monoclonal, chimeric, recombinatorial,
anti-idiotypic, humanized, or single chain antibodies, as well as fragments thereof
(see
Dubel and Breitling, Recombinant Antibodies, Wiley-Liss, New York, NY, 1999). Antibodies of the present invention are useful, for instance, in a variety of diagnostic
and therapeutic methods, based on state-in-the-art techniques (see
Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, New York, 1999 and
Edwards R., Immunodiagnostics: A Practical Approach, Oxford University Press, Oxford,
England, 1999) such as enzyme-immunoassays (e.g. enzyme-linked immunosorbent assay, ELISA), radioimmunoassays,
chemoluminescence-immunoassays, Western-blot, immunoprecipitation and antibody microarrays.
These methods involve the detection of translation products of the PPM1 E gene, or
fragments, or derivatives, or variants thereof.
[0053] In a preferred embodiment of the present invention, said antibodies can be used for
detecting the pathological state of a cell in a sample obtained from a subject, comprising
immunocytochemical staining of said cell with said antibody, wherein an altered degree
of staining, or an altered staining pattern in said cell compared to a cell representing
a known health status indicates a pathological state of said cell. Preferably, the
pathological state relates to a neurodegenerative disease, in particular to AD. Immunocytochemical
staining of a cell can be carried out by a number of different experimental methods
well known in the art. It might be preferred, however, to apply an automated method
for the detection of antibody binding, wherein the determination of the degree of
staining of a cell, or the determination of the cellular or subcellular staining pattern
of a cell, or the topological distribution of an antigen on the cell surface or among
organelles and other subcellular structures within the cell, are carried out according
to the method described in
US6150173.
[0054] Features and advantages of the invention will be apparent from the following description
of figures and examples, which are illustrative only and not intended to limit the
remainder of the disclosure in any way.
Description of the Figures
[0055]
Figure 1A: The table lists the data of differences in the levels of PPM1E gene derived
mRNA in human brain tissue samples from individuals corresponding to different Braak
stages indicative for AD as measured by quantitative RT-PCR analysis. It indicates
that the levels of the respective mRNA species correlate quantitatively with AD progression
and thus are indicative for AD as measured by the neuropathological staging of brain
tissue samples according to Braak and Braak (Braak staging). cDNA probes of frontal
cortex as well as of inferior temporal cortex each of 5 different donors with Braak
stage 0 (C011, C012, C026, C027, and C032), 7 different donors with Braak stage 1
(C014, C028, C029, C030, C036, C038, and C039), 5 different donors with Braak stage
2 (C008, C031, C033, C034, and DE03), 4 different donors with Braak stage 3 (C025,
DE07, DE11, and C057), and 3 different donors with Braak stage 4 (P012, P047, and
P068) have been applied to an analysis by quantitative RT-PCR using the Roche Lightcycler
rapid thermal cycling technique. The data were normalized to values of cyclophilin
B a standard gene that showed no significant differences in its gene expression levels.
The comparison between samples of the lowest Braak stage 0 with samples representing
Braak stages 1, 2 and 3 clearly demonstrates a substantial difference in gene expression
level of PPM1 E (see also Figure 1 B). Further, comparing Braak stage 0 with Braak
stages 1 and 2 indicates that differences of expression levels start already in very
early Braak stages.
Figure 1B: The graph demonstrates a substantial difference in gene expression level
of PPM1E by comparison between samples of frontal (F) and inferior temporal cortex
(T) representing different Braak stages.
Figure 2: The graph shows the analysis of absolute levels of PPM1E gene derived mRNA
in human brain tissue samples from individuals corresponding to different Braak stages
indicative for AD as measured by quantitative RT-PCR and using statistical method
of the median at 98%-confidence level (Sachs L (1988) Statistische Methoden: Planung und Auswertung. Heidelberg New York,
p. 60). The data were calculated by defining control groups including subjects with Braak
stages 0 to 1, which are compared with the data calculated for the defined groups
with advanced AD pathology including Braak stages 2 to 4. A significant difference
reflecting an up-regulation of PPM1E is shown comparing frontal (F) as well as inferior
temporal cortices (T) of Braak stage 0-1 with Braak stage 2-4 in frontal as well as
inferior temporal cortices. Said difference reflects an up-regulation of PPM1E in
the frontal cortex as well as in the inferior temporal cortex of individuals with
early AD pathology relative to the frontal cortex as well as to the inferior temporal
cortex of control persons.
Figure 3A: SEQ ID NO: 1, the amino acid sequence of the human PPM1E protein (full
length form, variant or derivative or fragment no. 1) (UniProt primary accession number
Q8WY54) comprising 775 amino acids is shown.
Figure 3B: SEQ ID NO: 2, the amino acid sequence of the human PPM1E protein (posttranslationally
truncated form, variant or derivative or fragment no. 2) comprising 557 amino acids
is shown.
Figure 4: SEQ ID NO: 3, the nucleotide sequence of the human PPM1E cDNA (Ensembl transcript
ID number ENST00000308249) encoding the PPM1E protein, comprising 6535 nucleotides
is shown.
Figure 5: SEQ ID NO: 4, the nucleotide coding sequence (cds) of the human PPM1E cDNA
(full length form) encoding the PPM1E full length protein, comprising 2268 nucleotides
is shown.
Figure 6: The sequence alignment of the primers used for PPM1E transcription level
profiling (primer A, SEQ ID NO: 5 and primer B, SEQ ID NO: 6) by quantitative RT-PCR
with the corresponding clippings of SEQ ID NO: 4, PPM1E coding cDNA sequence is shown.
Figure 7: The schematic drawing depicts the principle of a direct phosphatase assay.
The TAMRA-P1°* substrate having the amino acid sequence 5-TAMRA-AEEA-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH2
(p means phosphorylated) becomes dephosphorylated at the threonine residue in the
presence of the phosphatase. Upon dephosphorylation, the TAMRA-labelled P1°*-peptide
will no more bind to the polyclonal anti-active JNK antibody. As a results, a drop
of the fluorescence polarization is detected which is inversely proportional to phosphatase
activity.
Figure 8: The schematic drawing shows the principle of an indirect phosphatase assay.
In a first step, the bis-phosphorylated non-fluorescent P1°*-peptide (H-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH2)
is dephosphorylated by the activity of the phosphatase. The product of the reaction
(dephosphorylated P1°* peptide) will no more compete with the TAMRA-labelled P1°*-peptide
(5-TAMRA-AEEA-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH2) for the binding to
the polyclonal anti-active JNK antibody which are both added in a second step (stop
solution including a reagent inactivating the phosphatase).
Examples
Example 1:
Differential expression of PPM1E gene in human brain tissue samples.
[0056] In order to identify specific differences in the expression of genes that are associated
with AD, real-time quantitative PCR (qPCR) analyses were performed with a diversity
of mRNAs derived from human brain tissue specimens from clinically and neuropathologically
well characterized individuals. Verification of the differential expression of individual
genes was performed applying qPCR using gene-specific oligonucleotides. This technique
is widely used to generate expression profiles of multiple genes and to compare populations
of mRNA present in different tissue samples. In the present invention, mRNA populations
present in selected post-mortem brain tissue specimens (frontal and inferior temporal
cortex) were analyzed. Tissue samples were derived from individuals that could be
grouped into different Braak stages reflecting the full range between healthy control
individuals (Braak 0) and individuals that suffered from AD signs and symptoms (Braak
4). The methods were designed to specifically detect differences of expression levels
at early Braak stages, which is indicative for pathological events occurring early
in the course of the disease. Thus, said genes identified to be differential are effectively
implicated in the pathogenesis of AD.
(i) Brain tissue dissection from patients with AD:
[0057] Brain tissues from AD patients and age-matched control subjects, were collected.
Within 6 hours post-mortem time the samples were immediately frozen on dry ice. Sample
sections from each tissue were fixed in paraformaldehyde and neuropathologically staged
at various stages of neurofibrillary pathology according to Braak and Braak into Braak
stages (0-4). Brain areas for differential expression analysis were identified and
stored at -80 °C until RNA extractions were performed.
(ii) Isolation of total mRNA:
[0058] Total RNA was extracted from frozen post-mortem brain tissue by using the RNeasy
kit (Qiagen) according to the manufacturer's protocol. The accurate RNA concentration
and the RNA quality were determined applying the Eukaryote total RNA Nano LabChip
system by using the 2100 Bioanalyzer (Agilent Technologies). For additional quality
testing of the prepared RNA, i.e. exclusion of partial degradation and testing for
DNA contamination, specifically designed intronic GAPDH oligonucleotides and genomic
DNA as reference control were utilised to generate a melting curve with the LightCycler
technology (Roche) as described in the supplied protocol by the manufacturer.
(iii) Quantitative RT-PCR:
[0059] Identification and positive corroboration of differential PPM1E gene expression was
performed using the LightCycler technology (Roche). This technique features rapid
thermal cycling for the polymerase chain reaction as well as real-time measurement
of fluorescent signals during amplification and therefore allows for highly accurate
quantification of RT-PCR products by using a kinetic, rather than endpoint readout.
The relative quantity of PPM1E cDNAs from the frontal and temporal cortices of AD
patients and age-matched control individuals respectively, were determined in a number
of four up to nine tissues per Braak stage.
First, a standard curve was generated to determine the efficiency of the PCR with
specific primers for the gene coding for PPM1E:
Primer A, SEQ ID NO: 5, 5'-GTTCTGGATGGGACCGAAGA-3' (nucleotides 1264-1283 of SEQ ID
NO: 4) and Primer B, SEQ ID NO: 6, 3'-AAAGTTGTGTCCGACCACCTG-5' (nucleotides 1342-1362
of SEQ ID NO: 4).
PCR amplification (95°C and 1 sec, 56°C and 5 sec, and 72°C and 5 sec) was performed
in a volume of 20 µl containing LightCycler-FastStart DNA Master SYBR Green I mix
(contains FastStart Taq DNA polymerase, reaction buffer, dNTP mix with dUTP instead
of dTTP, SYBR Green I dye, and 1 mM MgCl2; Roche), 0.5 µM primers, 2 µl of a cDNA
dilution series (final concentration of 40, 20, 10, 5, 1 and 0.5 ng human total brain
cDNA; Clontech) and additional 3 mM MgCl2. Melting curve analysis revealed a single
peak at approximately 86°C with no visible primer dimers. Quality and size of the
qPCR product were determined applying the DNA 500 LabChip system using the 2100 Bioanalyzer
(Agilent Technologies). A single peak at the expected size of 99 bp for the gene coding
for PPM1 E protein was observed in the electropherogram of the sample.
In an analogous manner, the qPCR protocol was applied to determine the PCR efficiency
of cyclophilin B, using the specific primers SEQ ID NO: 7, 5'-ACTGAAGCACTACGGGCCTG-3'
and SEQ ID NO: 8, 5'-AGCCGTTGGTGTCTTTGCC-3' except for MgCl2 (an additional 1 mM was
added instead of 3 mM). Melting curve analysis revealed a single peak at approximately
87°C with no visible primer dimers. Bioanalyzer analysis of the PCR product showed
one single peak of the expected size (62 bp).
For calculation of the standard values, first the logarithm of the used cDNA concentration
was plotted against the threshold cycle value Ct for PPM1E and Cyclophilin B respectively.
The slopes and the intercepts of the standard curves (i.e. linear regressions) were
calculated. In a second step, mRNA expression from frontal and inferior temporal cortices
of controls and AD patients were analyzed in parallel. The Ct values were measured
and converted to ng total brain cDNA using the corresponding standard curves:
![](https://data.epo.org/publication-server/image?imagePath=2009/18/DOC/EPNWA1/EP07119261NWA1/imgb0001)
Calculated cDNA concentration values were normalized to Cyclophilin B that was analyzed
in parallel for each tested tissue probe, thus resulting values are defined as arbitrary
relative expression levels. The results of such quantitative RT-PCR analysis for the
gene coding for PPM1 E protein are shown in Figure 1A and Figure 1B.
(iv) Statistical analysis of the mRNA expression comparing donor groups with different
Braak stages.
[0060] For this analysis it was proven that absolute values of real-time quantitative PCR
(Lightcycler method) between different experiments at different time points are consistent
enough to be used for quantitative comparisons without usage of calibrators. Cyclophilin
was used as a standard for normalization in any of the qPCR experiments for more than
100 tissues. Between others it was found to be the most consistently expressed housekeeping
gene in the normalization experiments. Therefore a proof of concept was done by using
values that were generated for cyclophilin.
First analysis used cyclophilin values from qPCR experiments of frontal cortex and
inferior temporal cortex tissues from three different donors. From each tissue the
same cDNA preparation was used in all analyzed experiments. Within this analysis no
normal distribution of values was achieved due to small number of data. Therefore
the method of median and its 98 %-confidence level was applied (
Sachs L (1988) Statistische Methoden: Planung und Auswertung. Heidelberg New York,
p. 60). This analysis revealed a middle deviation of 8.7 % from the median for comparison
of absolute values and a middle deviation of 6.6 % from the median for relative comparison.
Second analysis used cyclophilin values from qPCR experiments of frontal cortex and
inferior temporal cortex tissues from two different donors each, but different cDNA
preparations from different time points were used. This analysis revealed a middle
deviation of 29.2 % from the median for comparison of absolute values and a middle
deviation of 17.6 % from the median for relative comparison. From this analysis it
was concluded, that absolute values from qPCR experiments can be used, but the middle
deviation from median should be taken into further considerations.
[0061] A detailed analysis of absolute values for PPM1E was performed using the method of
median and its 98 %-confidence level. Because in contrast to the mean the calculation
of the median is not affected by single data outliers; therefore latter is the method
of choice for a small number of data that are distributed non-normal and/or assymetric
(
Sachs L (1988) Statistische Methoden: Planung und Auswertung. Heidelberg New York,
p. 60). Therefore, absolute levels of PPM1 E were used after relative normalization with
cyclophilin. The median as well as the 98 %-confidence level was calculated for a
group consisting of low level Braak stages (Braak 0 - Braak 1) and the group consisting
of high level Braak stages (Braak 2 - Braak 4). The analysis was aimed to identify
early onset of mRNA expression differences within the course of AD pathology. Said
analysis described above is shown in Figure 2.
Example 2:
Screening for PPM1E activity using enzymatic assays
(i) Dephosphorylation of TAMRA-P1°* Peptide by PPM1E Phosphatase using a direct phosphatase
assay (Figure 7).
[0062] Efficient dephosphorylation of the P1°*-TAMRA substrate peptide using the direct
phosphatase assay is performed as follows: In a total volume of 80 µl (Assay buffer:
50 mM HEPES, 10 mM MgCl
2, 2 mM MnCl
2, 1 mM DTT; pH 7.2) the P1°*-TAMRA substrate peptide 5-TAMRA-AEEA-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH2
(at 10 nM) is dephosphorylated using 0.1, 0.01, or 0,001 units of PPM1E. The phosphatase
reactions are incubated at 30 °C and aliquots (20 µl) are withdrawn after 0 min, 30
min, 60 min and 90 min and mixed with 10 µl of a stop solution containing the following
reagents (all final concentrations): hydrogenperoxide 10 mM, polyclonal anti-active
JNK antibody (NEB, U.S.A.: NEB #9251) at a dilution of 1:20.
The formed dephosphorylated P1°*-TAMRA peptide product can be detected as it does
not bind to the polyclonal anti-active JNK antibody. As a result, a drop of the fluorescence
polarization is detected which is inversely proportional to PPM1E phosphatase activity.
(ii) Dephosphorylation of non-fluorescent P1°* Peptide by PPM1 E Phosphatase in an
indirect phosphatase assay (Figure 8).
[0063] PPM1E phosphatase (0.5 units) is incubated with 100 nM or 500 nM bisphosphorylated
P1°* substrate peptide (H-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH2) in a
total volume of 80 µl at 30 °C (Assay buffer: 50 mM HEPES, 10 mM MgCl
2, 2 mM MnCl
2, 1 mM DTT; pH 7.2). In a second step, at different time points, aliquots (20 µl)
are withdrawn from the enzyme reaction and mixed with 10 µl of the stop solution containing
hydrogen peroxide (10 nM), TAMRA-P1°* peptide (5-TAMRA-AEEA-Lys-Phe-Met-Met-pThr-Pro-pTyr-Val-Val-Thr-Arg-NH2)
(5 nM) together with the polyclonal anti active JNK antibody (NEB, U.S.A.; NEB #9251)
(1:20 dilution).
As a result of the PPM1E activity, the P1°* substrate peptide is dephosphorylated
and does no longer compete with the TAMRA-P1°* peptide for the binding to the polyclonal
anti active JNK antibody. This can be detected by an increase in fluorescence polarization.
(iii) Phosphatase assay with monophosphorylated substrates.
[0064] The activity of PPM1E is measured in a phosphatase assay using a monophosphorylated
substrate. The substrates may be either monophosphorylated proteins or monophosphorylated
peptides which are purified or synthetic substrates. The state of phosphorylation
of the substrate is measured after allowing PPM1E to react with the substrate. The
change of phosphorylation of the substrate, the dephosphorylation by the phosphatase
PPM1 E, the phosphatase activity of PPM1 E is determined.
The method can be used either in a direct, an indirect or a competitive assay format
as described in the present invention under (i) and (ii).